Podcast: How Trump's tariffs will impact clinical trials [Yahoo! Finance]
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Yahoo! Finance
Clinical Trials Arena · JuShoot / Shutterstock Abigail Beaney Mon, February 17, 2025 at 1:39 PM GMT+1 1 min read Trump's tariffs are set to impact all sectors in some capacity, including clinical trials. With the US President placing a 10% levy on imports from China, this will have a significant impact on the cost of drugs, especially generics, which are set to soar. Tariffs could also lead to shortages of generics in the US, many of which are used as active controls in trials. The Clinical Trials Arena team spoke to Doug Drysdale, CEO of Cybin, a biotech developing psychedelics, and Anshul Mangal, president of Project Farma, a consulting firm for biomanufacturing strategy and execution, to discuss the impacts expected in the sector. You can listen to the podcast
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin wins new Buy from Guggenheim: potential to challenge J&J's Spravato cited [Seeking Alpha]Seeking Alpha
- Cybin Inc. (NYSE: CYBN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.MarketBeat
- Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at HC Wainwright from $190.00 to $150.00. They now have a "buy" rating on the stock.MarketBeat
- Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $86.00 to $73.00. They now have a "buy" rating on the stock.MarketBeat
- Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business HighlightsBusiness Wire
CYBN
Earnings
- 6/26/24 - Miss
CYBN
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form 6-K
- 2/14/25 - Form SCHEDULE
- CYBN's page on the SEC website